Michael Mullan received his Medical Degree from London University in 1985, an MRCPsych from the Royal College of Psychiatrists in 1990, and began presenting the results of his research on Alzheimer’s disease in 1989 in England and in Vienna, at the European Association of Geriatric Psychiatry Annual Symposium. In 1990, he was invited to present his findings in Canada and East Germany. From that time on, Mullan has made great progress in his field – particularly with regard to molecular genetics, and has continued sharing his important work with colleagues and others at conferences and professional meetings and symposiums around the globe. In addition, Mullan has been appointed Chief Executive Officer of the Roskamp Institute in Sarasota, Florida. Michael Mullan currently serves as Chief Executive Officer of the Roskamp Institute, the CEO and Chief Scientific Officer of Archer Pharmaceuticals, Inc., and President of Sci-Brain.
One area of Mullan’s work that has gained widespread attention is his research on Alzheimer’s disease identification of the Swedish Mutation, which is present in familial forms. He holds several patents which cover the application of APP mutations. While it is believed that brain plaques and tangles in intricate brain networks figure into the equation, the exact cause of Alzheimer’s, which is an irreversible, degenerative disease that affects memory, has not yet been determined. Any research that sheds greater light on the causes of Alzheimer’s, or genetic predictors, can be a vital stepping stone to finding suitable cures and treatments.
The Roskamp Institute was established in 2003 in order to research Alzheimer’s, along with a range of neurological issues. Dr. Mullan’s professional achievements as a researcher, lecturer and educator made him the perfect choice to lead the Institute and when the Institute opened its doors it was with Mullan at the lead, as CEO. Researchers at the Institute are able to take advantage of the state of the art facilities to investigate the relationship between age related diseases and inflammation in aging and vascular factors to the onset and progression of Alzheimer’s, as well as other issues such as the genomes and proteomics of drug abuse, attention deficit / hyperactivity disorder (ADHD), Tourette’s syndrome and TBI (Traumatic Brain Injury). When the Institute opened Archer Drugs in 2008 to target the discovery of medical treatment for Alzheimer’s, Mullan was name CEO and Chief Scientific Officer.
As part of his work at the Roskamp Institute, Dr. Michael Mullan serves as Director of the RIMC (Roskamp Institute Memory Center), leading a team of top notch neuroradiology, geriatrics and neuropsychology professionals. The RIMC provides free memory screens for people over who are 60. The memory screen, which is made up of a written questionnaire that can be completed at the clinic or at home, and a short memory test administered at the RIMC, is used for early detection of dementia. Early detection can enhance the affectivity of some forms of treatment and enables patients to plan for future needs. In addition to memory screening, the RIMC conducts a wide range of assessments which can be used to diagnose the source of relevant issues and to come up with appropriate treatment options, including agency referrals, long term planning, and patient follow up.